Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

First-in-human clinical evaluation of a sustained-release exenatide for the treatment of diabetes

Feb. 11, 2014

Metabrain Research divulges compounds with potential for treatment of type 2 diabetes

Feb. 10, 2014

Chinese researchers patent novel CETP inhibitors

Feb. 10, 2014

Zosano Pharma and Novo Nordisk enter agreement to develop transdermal formulation of semaglutide

Feb. 6, 2014

New benzothiazole derivatives synthesized by Bristol-Myers Squibb for dyslipidemia

Feb. 6, 2014

Scientists at Bayer Schering Pharma divulge new AKR1C3 inhibitors

Feb. 5, 2014

Scientists in China synthesize new CETP inhibitors

Feb. 4, 2014

AstraZeneca completes purchase of Bristol-Myers Squibb's global diabetes business

Feb. 4, 2014

Alethia Biotherapeutics patents new humanized MAbs for bone disorders

Feb. 3, 2014

Amgen's RUTHERFORD-2 phase III trial of evolocumab in HeFH meets primary endpoints

Jan. 31, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...